Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients

Haematologica

Volumn 92, Issue 8, 2007, Pages 1123-1126

  Silva, Fernando P G ^a   Lind, Alexandra ^a   Brouwer Mandema, Geeske ^a   Valk, Peter J M ^b   Giphart Gassler, Micheline ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; AML M0; FLT3; RUNX1; Trisomy 13

Indexed keywords

FLT3 LIGAND; MESSENGER RNA; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; RNA; RUNX1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RUNX1; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL SURFACE; CONTROLLED STUDY; GENE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; RUNX1 GENE; TRISOMY 13; ACUTE DISEASE; BIOSYNTHESIS; CLASSIFICATION; COHORT ANALYSIS; EXON; GENE EXPRESSION REGULATION; GENETICS; KARYOTYPING; METABOLISM; MUTATION; MYELOID LEUKEMIA; PHYSIOLOGY; TRISOMY;

ACUTE DISEASE; COHORT STUDIES; CORE BINDING FACTOR ALPHA 2 SUBUNIT; EXONS; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; MUTATION; NEOPLASM PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; TRISOMY;

EID: 35748939738     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11296     Document Type: Article

References (23)

1. Dohner H, Arthur DC, Ball ED, Sobol RE, Davey FR, Lawrence D, et al. Trisomy 13: a new recurring chromosome abnormality in acute leukemia. Blood 1990;76:1614-21.
2. Mertens F, Sallerfors B, Heim S, Johansson B, Kristoffersson U, Malm C, et al. Trisomy 13 as a primary chromosome aberration in acute leukemia. Cancer Genet Cytogenet 1991;56:39-44.
3. Baer MR, Bloomfield CD Trisomy 13 in acute leukemia. Leuk Lymphoma 1992;7:1-6.
4. Klaus M, Haferlach T, Schnittger S, Kern W, Hiddemann W, Schoch C Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization. Cancer Genet Cytogenet 2004; 155:47-56.
5. Sreekantaiah C, Baer MR, Morgan S, Isaacs JD, Miller KB, Sandberg AA Trisomy/tetrasomy 13 in seven cases of acute leukemia. Leukemia 1990; 4:781-5.
6. Mehta AB, Bain BJ, Fitchett M, Shah S, Secker-Walker LM Trisomy 13 and myeloid malignancy: characteristic blast cell morphology: a United Kingdom Cancer Cytogenetics Group survey. Br J Haematol 1998; 101:749-52.
7. Cuneo A, Ferrant A, Michaux JL, Boogaerts M, Demuynck H, Van Orshoven A, et al. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. Blood 1995;85:3688-94.
8. Farag SS, Archer KJ, Mrozek K, Vardiman JW, Carroll AJ, Pettenati MJ, et al. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol 2002; 21:1041-51.
9. Kiyoi H, Naoe T FLT3 in human hematologic malignancies. Leuk Lymphoma 2002;43:1541-7.
10. Reilly JT FLT3 and its role in the pathogenesis of acute myeloid leukaemia. Leuk Lymphoma 2003; 44:1-7.
11. Gilliland DG, Griffin JD The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42.
12. Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004; 103:1901-8.
13. Silva FP, Morolli B, Storlazzi CT, Anelli L, Wessels H, Bezrookove V, et al. Identification of RUNX1/AML1 as a classical tumor suppressor gene. Oncogene 2003;22:538-47.
14. Powell H, Curtis A, Bown N, Taylor P. No correlation between trisomy 13 and FLT3 duplication in acute myeloid leukemia. Cancer Genet Cytogenet 2005;156:92-3.
15. Osato M Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene 2004; 23:4284-96.
16. Mikhail FM, Sinha KK, Saunthararajah Y, Nucifora G Normal and transforming functions of RUNX1: a perspective. J Cell Physiol 2006;207:582-93.
17. Tefferi A, Pardanani A Mutation screening for JAK2V617F: when to order the test and how to interpret the results. Leuk Res 2006;30:739-44.
18. Frohling S, Scholl C, Gilliland DG, Levine RL Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005; 23:6285-95.
19. Rucker FG, Bullinger L, Schwaenen C, Lipka DB, Wessendorf S, Frohling S, et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006;24:3887-94.
20. Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, et al. Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica 2005;90:1617-25.
21. Rosnet O, Buhring HJ, Marchetto S, Rappold I, Lavagna C, Sainty D, et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996;10:238-48.
22. Roumier C, Eclache V, Imbert M, Davi F, Macintyre E, Garand R, et al. M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francais d'Hématologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood 2003;101:1277-83.
23. Dicker F, Schoch C, Haferlach T, Kern W, Schnittger S. Trisomy 13 defines a subgroup of myeloid malignancies with an extremely high frequency of AML1 gene mutations and newly defined VEGFR-1 Mutations [Abstract]. Blood 2006;108.